Based on the available information, there is limited data regarding the use of Cosentyx (secukinumab) during pregnancy. The U.S. Food and Drug Administration (FDA) has classified secukinumab as a pregnancy category B drug, which means that animal studies have not shown a risk to the fetus, but there are no well-controlled studies in pregnant women [2].

The manufacturer's label for Cosentyx states that "available data from published literature and postmarketing experience do not suggest an increased risk of major birth defects, miscarriage or adverse maternal or fetal outcomes when administered during pregnancy" [3]. However, it is still advised to use Cosentyx during pregnancy only if the potential benefit justifies the potential risk to the fetus [3].

A recent review of secukinumab in pregnancy and lactation concluded that "there is insufficient evidence to determine the safety of secukinumab in pregnancy and lactation" [1]. The authors recommend that "decisions regarding the use of secukinumab during pregnancy and lactation should be made on a case-by-case basis after discussion with the patient" [1].

In summary, while there is no clear evidence of harm, the use of Cosentyx during pregnancy should be carefully considered and discussed with a healthcare provider.

Sources:
[1] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/>
[2] <https://www.drugs.com/pregnancy/secukinumab.html>
[3] <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>